Dermatomyositis and polymyositis: clinical aspects.
D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D001379:Azathioprine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001706:Biopsy; D002114:Calcinosis / Q000150:complications; D003402:Creatine Kinase / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003680:Deglutition Disorders / Q000150:complications; D003882:Dermatomyositis / Q000150:complications / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D004359:Drug Therapy, Combination; D006331:Heart Diseases / Q000150:complications; D006801:Humans; D008168:Lung / Q000473:pathology; D008171:Lung Diseases / Q000150:complications / Q000000981:diagnostic imaging; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D009132:Muscles / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D009211:Myoglobin / Q000378:metabolism; D009220:Myositis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D011859:Radiography; D012867:Skin / Q000473:pathology
D000305:Adrenal Cortex Hormones; D009211:Myoglobin; D003520:Cyclophosphamide; D003402:Creatine Kinase; D001379:Azathioprine; D008727:Methotrexate